Showing results (51-60 of 89) with videos related to
Sort By:
Pageof 9
Cancer Letters|October 2, 2023
Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagyYuxin Zhang, Yujie Zhang, Haisu Tao, et al.Cancer Communications (London, England)|May 30, 2025
Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinomaJinghan Zhu, Yixiao Xiong, Yuxin Zhang, et al.Science China. Life Sciences|April 23, 2026
The liver-bone axis: an emerging player in disease pathogenesis and therapeutic interventionShenqi Han, Yi Wei, Guanxing Yu, et al.BJS Open|March 23, 2026
Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombusBin Guo, Shaliheng Yerken, Chu Luo, et al.Nature Communications|October 24, 2013
Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinomaRuihua Ma, Wanguang Zhang, Ke Tang, et al.Lung|May 14, 2014
Diaphragmatic motion studied by M-mode ultrasonography in combined pulmonary fibrosis and emphysemaLi He, Wanguang Zhang, Jiahong Zhang, et al.Gut|July 31, 2025
Targeting Aurora kinase B regulates cholesterol metabolism and enhances chemoimmunotherapy in cholangiocarcinomaFurong Liu, Wei Chen, Ze Zhang, et al.Cancer Biology & Therapy|September 13, 2013
Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancerXi Ai, Yanhui Wu, Wei Zhang, et al.Gut|December 20, 2023
Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8<sup>+</sup> T cell-mediated antitumour immunity and improves anti-PD-1 efficacyNing Cai, Kun Cheng, Yue Ma, et al.Acta Pharmaceutica Sinica. B|February 13, 2026
Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinomaYue Ma, Chenhe Yi, Ning Cai, et al.Pageof 9